CHMP Recommends EU Approval for Sanofi's Innovative Sarclisa On-Body Injector for Multiple Myeloma
SNY is trading near its 52-week low of $43.32 (9.4% above the low).
Summary
Sanofi's Sarclisa subcutaneous formulation, administered via an on-body injector, has received a positive recommendation for EU approval from the CHMP to treat multiple myeloma. This recommendation is based on studies demonstrating comparable efficacy, pharmacokinetics, and safety to the intravenous formulation. If approved, this would mark a significant advancement as Sarclisa would be the first available anticancer treatment delivered through an on-body injector and the only anti-CD38 monoclonal antibody in multiple myeloma offering both on-body injector and manual subcutaneous injection flexibility in the EU. This development is highly positive for Sanofi, as it enhances patient convenience and could significantly improve Sarclisa's competitive positioning and market penetration. A final decision from the European Commission is anticipated in the coming months.
At the time of this announcement, SNY was trading at $47.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $112.6B. The 52-week trading range was $43.32 to $56.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.